In Vitro Exploration of EGFR in Breast Cancer: Unlocking the Cellular Signaling Network

Dr. Pravin Badhe, Ashwini Badhe

Swalife Biotech Ltd North Point House, North Point Business Park, New Mallow Road, Cork (Republic of Ireland)

Corresponding author: drpravinbadhe@swalifebiotech.com
Doi: https://doi.org/10.5281/zenodo.17897028
Received: 12 September 2025
Accepted: 22 October 2025

Abstract:

Breast cancer remains a leading cause of cancer-related mortality worldwide, with an estimated 2.3 million new cases and 670,000 deaths in 2022, and projections indicating a continued rise in incidence by 1–5% annually in many regions. The epidermal growth factor receptor (EGFR) plays a pivotal role in tumor progression, particularly through its overexpression in aggressive subtypes such as triple-negative breast cancer (TNBC) and HER2-positive breast cancer, where it drives proliferation, invasion, and therapeutic resistance. This review explores how in vitro models have illuminated the intricate cross-talk between EGFR and estrogen receptor (ER) pathways, revealing mechanisms of bidirectional signaling that exacerbate endocrine resistance and metastatic potential. EGFR overexpression in TNBC correlates with heightened aggressiveness and poor prognosis, while in HER2-positive tumors, it contributes to resistance against antibody-drug conjugates like trastuzumab deruxtecan, underscoring the need for dual-targeting strategies. Cell-based assays, including MTT for viability, wound-healing for migration, and Western blot for phosphorylation events, have been instrumental in validating EGFR inhibitors' efficacy and dissecting pathway interactions in 2D and 3D models like MDA-MB-231 and MCF-7 cells. Furthermore, network pharmacology approaches have predicted phytochemicals (e.g., from Nigella sativa or Eclipta prostrata) that disrupt EGFR signaling hubs, offering multi-target potential with reduced resistance risks. By synthesizing these in vitro insights, this article highlights opportunities for precision therapeutics, emphasizing the transition from cellular networks to clinical applications in overcoming breast cancer heterogeneity

Keywords: Epidermal Growth Factor Receptor (EGFR), Breast Cancer Subtypes, EGFR-Estrogen Receptor Cross-Talk, In Vitro Models, Triple-Negative Breast Cancer (TNBC), Cell-Based Assays, Network Pharmacology, Phytochemicals

Introduction:

Breast cancer is the most common malignancy among women globally, accounting for approximately 25% of all female cancers and posing a significant public health challenge. In 2025, the United States alone anticipates 316,950 new cases of invasive breast cancer among women, alongside 2,800 cases in men, and an additional 59,080 diagnoses of ductal carcinoma in situ (DCIS). Worldwide, the burden is even more pronounced, with 2.3 million incident cases and 670,000 deaths reported in 2022, driven by aging populations, lifestyle factors, and disparities in screening and access to care. Projections from the International Agency for Research on Cancer (IARC) suggest that, based on current trends, one in 20 women will develop breast cancer in their lifetime, with incidence rates escalating in low- and middle-income countries due to westernization of diets and delayed childbearing.[1] The disease's heterogeneity is a hallmark, classified into molecular subtypes—luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC)—each with distinct clinical behaviors, therapeutic responses, and prognostic outcomes. TNBC, comprising 15–20% of cases, is particularly aggressive, lacking expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), leading to limited targeted options and high recurrence rates. In contrast, HER2-positive tumors (15–20% of cases) overexpress HER2, conferring rapid proliferation but responsiveness to HER2-directed therapies. Despite advances in immunotherapy and chemotherapy, resistance mechanisms persist, necessitating deeper interrogation of underlying signaling networks.[2]

At the molecular core of these aggressive phenotypes lies the epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor of the ErbB family that orchestrates cell growth, survival, and motility. EGFR, also known as ErbB1, features an extracellular ligand-binding domain, a transmembrane helix, and an

intracellular kinase domain that, upon binding ligands like epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-α), undergoes dimerization and autophosphorylation. This activates canonical downstream cascades, including the mitogen-activated protein kinase (MAPK/ERK) pathway for proliferation, the phosphoinositide 3-kinase (PI3K/AKT) axis for anti-apoptosis, and phospholipase C-γ (PLC-γ) for invasion.[3] In breast cancer, EGFR deregulation—through gene amplification, mutations, or ligand overexpression—occurs in up to 87% of TNBC cases, associating with lymph node metastasis, chemoresistance, and reduced overall survival. Similarly, in HER2-positive subtypes, EGFR co-overexpression (observed in 40–50% of cases) fosters heterodimerization with HER2, amplifying signaling and contributing to resistance against trastuzumab and antibody-drug conjugates like trastuzumab deruxtecan (T-DXd). Recent multi-omics analyses confirm EGFR as a central hub, intertwining with PI3K/AKT and MAPK/ERK to sustain tumor microenvironment interactions and immune evasion. These insights position EGFR as a compelling therapeutic target, yet monotherapy failures highlight the complexity of its integration with other oncogenic pathways, particularly the ER axis.[4]

In vitro models have emerged as indispensable tools for unraveling this complexity, offering controlled environments to dissect EGFR's interactions without the confounding variables of in vivo systems, such as tumor-stroma dynamics or systemic immune responses. Traditional 2D monolayer cultures, like ER-positive MCF-7 and TNBC MDA-MB-231 cell lines, enable high-throughput manipulation via CRISPR/Cas9 or small-molecule inhibitors, while 3D organoids and spheroids better recapitulate tumor architecture, hypoxia, and drug penetration. A key revelation from these models is the bidirectional cross-talk between EGFR and ER pathways, where EGFR ligands transactivate nuclear ER through MAPK-mediated phosphorylation of serine 118, enhancing estrogen-independent proliferation and endocrine therapy resistance. Reciprocally, membrane ER can allosterically activate EGFR, amplifying HER2 signaling in resistant cells.[5] Recent studies in tamoxifen-resistant lines demonstrate that EGFR inhibition restores ER antagonist sensitivity, underscoring this interplay's clinical relevance. Moreover, in vitro assays—such as MTT for metabolic viability, wound-healing for migratory phenotypes, and Western blotting for phospho-protein dynamics—have quantified these effects, revealing subtype-specific vulnerabilities. Complementing these experimental approaches, network pharmacology employs computational modeling to predict phytochemical modulators (e.g., thymoquinone from Nigella sativa) that target EGFR hubs, validated in cell lines for synergistic pathway disruption.[6]

This review synthesizes in vitro evidence to unlock the EGFR-ER signaling network in breast cancer, emphasizing EGFR's overexpression in TNBC and HER2-positive subtypes, the utility of cell-based assays for inhibition studies, and network pharmacology's role in identifying novel phytochemicals. By bridging cellular mechanisms to therapeutic innovation, these insights pave the way for personalized interventions that mitigate cross-talk-driven resistance.

EGFR Overexpression in Breast Cancer Subtypes

Deregulation of the epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is a hallmark of aggressive breast cancer phenotypes, driven primarily by gene amplification, activating mutations, and ligand overexpression. EGFR amplification, observed in up to 24% of triple-negative breast cancer (TNBC) cases and less frequently in other subtypes (0.8–14% overall), results in constitutive receptor activation and heightened downstream signaling via pathways such as MAPK/ERK and PI3K/AKT, promoting proliferation and survival.[7] Activating mutations in the EGFR kinase domain, including exon 19 deletions and L858R substitutions in exon 21, are rare in breast cancer (<1% overall) but occur in approximately 11% of TNBC tumors, often co-existing with amplification to enhance ligand-independent signaling. Ligand overexpression, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), fosters autocrine/paracrine loops that sustain EGFR activation even without genetic alterations, contributing to therapy resistance through impaired endocytosis and accelerated receptor recycling. These mechanisms collectively amplify EGFR's oncogenic potential, particularly in hormone receptor-negative contexts, underscoring its role as a therapeutic vulnerability.[8]

In TNBC, which accounts for 15–20% of breast cancers and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, EGFR overexpression is markedly prevalent, reported in 50–87% of cases depending on detection methods like immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).[9] This high expression correlates with basal-like features, including elevated Ki-67 proliferation indices (up to 45%) and TP53 mutations (35%), fostering an aggressive phenotype with rapid metastasis and chemoresistance. Prognostically, EGFR overexpression portends poor outcomes: high gene copy number independently predicts reduced disease-free survival (DFS; hazard ratio [HR] 2.39, 95% CI 1.32–4.34), while combined EGFR/HER3 scoring enhances predictive power for overall survival (OS) and response to adjuvant chemotherapy. In vitro studies using TNBC cell lines like MDA-MB-231 demonstrate that EGFR-driven PI3K/PTEN axis alterations impair anti-EGFR drug efficacy, highlighting therapeutic vulnerabilities such as synthetic lethality with PARP inhibitors in high-EGFR

contexts. Despite these insights, clinical trials of EGFR tyrosine kinase inhibitors (TKIs) like gefitinib have shown limited efficacy as monotherapy, emphasizing the need for combinatorial strategies.[10]

EGFR deregulation is also prominent in HER2-positive breast cancer (15–20% of cases), where co-overexpression occurs in 40–50% of tumors, facilitating heterodimerization that amplifies signaling potency beyond HER2 homodimers. This overlap activates shared downstream effectors like AKT and ERK, exacerbating endocrine resistance in hormone receptor-positive/HER2-positive subsets via ER/HER2 crosstalk. Clinically, EGFR co-expression associates with trastuzumab resistance, as seen in models where high EGFR limits HER2 antibody-drug conjugate (ADC) internalization, reducing DFS (HR 2.34, 95% CI 1.20–4.59) in adjuvant settings. In vitro evidence from HER2-amplified lines like BT-474 reveals that EGFR/HER2 complexes translocate to mitochondria and nucleus, sustaining kinase-independent oncogenesis; dual degradation via agents like PEPDG278D obliterates these signals, restoring sensitivity to trastuzumab deruxtecan (T-DXd). Co-targeting strategies, including EGFR/HER2 TKIs like neratinib or lapatinib, have shown promise in overcoming resistance, with phase III trials (e.g., HER2CLIMB) supporting tucatinib combinations for advanced disease.[11]

Comparatively, EGFR expression is highest in TNBC (50–60%) versus HER2-positive tumors (40–50% co-expression), reflecting subtype-specific drivers: amplification dominates in TNBC for de novo aggression, while heterodimerization prevails in HER2-positive for adaptive resistance. Both confer poor prognosis—worse OS/DFS in TNBC (HR up to 2.39) and trastuzumab-refractory DFS in HER2-positive—but in vitro disparities emerge: TNBC models exhibit greater EGFR/PI3K interdependence, vulnerable to multi-kinase inhibition, whereas HER2-positive lines benefit from ADC-EGFR antibody synergies. These differences, validated in CRISPR-edited 2D/3D cultures, inform subtype-tailored therapies, though intratumoral heterogeneity complicates translation[12]

Feature	TNBC	HER2-Positive Breast Cancer
EGFR Expression Level	50–87% (high IHC/FISH)	40–50% co-expression
Key Deregulation	Amplification (up to 24%), rare mutations	Heterodimerization, ligand loops
Clinical Outcomes	Poor DFS/OS (HR 2.39); high metastasis	Trastuzumab resistance; reduced DFS (HR 2.34)
Subtype-Specific Inhibitors	Gefitinib + PARP (limited); cetuximab combos	Neratinib/lapatinib (dual TKI); T-DXd + EGFR mAb

In Vitro Models of EGFR-ER Cross-Talk:

The intricate interplay between the epidermal growth factor receptor (EGFR) and estrogen receptor (ER) pathways represents a critical driver of breast cancer progression and therapeutic resistance, particularly in hormone receptor-positive (HR+) subtypes where endocrine therapies like tamoxifen or aromatase inhibitors often fail due to adaptive signaling rerouting. In vitro models have been pivotal in dissecting this cross-talk, providing a controlled platform to manipulate molecular components and observe dynamic interactions that are challenging to isolate in vivo. These systems range from simple two-dimensional (2D) monolayers to sophisticated three-dimensional (3D) architectures that more faithfully mimic the tumor microenvironment (TME), including extracellular matrix (ECM) stiffness, hypoxia, and stromal interactions. By leveraging cell lines, co-cultures, and advanced organoids, researchers have uncovered bidirectional signaling loops that amplify oncogenic outputs, informing the development of combination therapies targeting both receptors.[13]

Overview of In Vitro Models

Traditional 2D cell culture models, such as the ER-positive MCF-7 and T-47D lines, have served as foundational tools for EGFR-ER studies due to their accessibility, scalability, and ease of genetic manipulation. MCF-7 cells, derived from pleural effusion of a metastatic breast adenocarcinoma, express high levels of ERα and low basal EGFR, allowing investigators to introduce EGFR overexpression via lentiviral transduction or ligand stimulation (e.g., EGF) to simulate cross-talk. Similarly, BT-474 cells, which overexpress both ER and HER2 (with EGFR co-expression), model HR+/HER2+ disease and have been used to probe heterodimerization effects on ER activity. These monolayers enable high-throughput assays but often overlook spatial heterogeneity and cell-ECM interactions, leading to discrepancies in drug responses compared to tumors.[14]

To address these limitations, 3D models like spheroids and organoids have gained prominence. Multicellular tumor spheroids (MCTS), formed by low-adherence plating of MCF-7 or MDA-MB-468 (EGFR-high TNBC) cells, recapitulate nutrient gradients and quiescent cores akin to avascular tumor regions. Patient-derived organoids (PDOs), cultured in Matrigel with growth factors, preserve subtype-specific features; for instance, ER+ PDOs from primary tumors exhibit ligand-inducible EGFR-ER synergy, with enhanced cyclin D1 expression under EGF exposure.

Co-culture systems further enhance physiological relevance by incorporating stromal fibroblasts or immune cells, revealing how paracrine signals (e.g., EGF from cancer-associated fibroblasts) amplify ER transactivation in MCF-7 monocultures. Recent advancements, including microfluidic organ-on-chip platforms, simulate vascular perfusion and shear stress, demonstrating that fluid dynamics modulate EGFR ligand availability and ER phosphorylation in 3D ER+ breast cancer models.[15]

Mechanisms of Cross-Talk

The EGFR-ER axis operates through bidirectional mechanisms that converge on shared downstream effectors, perpetuating a feed-forward loop of proliferation and survival. EGFR transactivation of ER is a dominant pathway, wherein EGF binding induces receptor dimerization and autophosphorylation, activating the MAPK/ERK cascade that phosphorylates ERα at serine 118 (S118). This post-translational modification enhances ER's transcriptional activity on estrogen response elements (EREs), even in low-estrogen conditions, upregulating genes like CCND1 (cyclin D1) and MYC to drive G1/S transition. In vitro evidence from MCF-7 cells transfected with constitutively active EGFR mutants confirms this: ERK inhibition with U0126 abolishes S118 phosphorylation and restores tamoxifen sensitivity.[16]

Reciprocally, ER can non-genomically activate EGFR via membrane-associated pools. Estrogen (E2) binding to membrane ERα (mER) recruits Src kinase, leading to metalloproteinase-mediated shedding of pro-EGFR ligands like amphiregulin (AREG), which then bind and activate EGFR in an autocrine manner. This rapid signaling (within minutes) sustains PI3K/AKT activation, inhibiting apoptosis through FOXO3a sequestration. Shared effectors further entwine the pathways: both converge on mTORC1 to boost protein synthesis and on AP-1 (c-Fos/Jun) for invasive gene expression, as observed in BT-474 co-stimulation experiments where E2+EGF synergistically elevates MMP9 levels. Nuclear cross-talk adds complexity, with phosphorylated ER translocating to EGFR promoters, forming enhanceosomes that amplify EGFR transcription in long-term cultures.[17]

Evidence from In Vitro Studies

In vitro paradigms have provided compelling evidence for ligand-induced synergy and its role in endocrine resistance. In MCF-7 cells, chronic EGF exposure upregulates ER S118 phosphorylation and AREG expression, conferring partial resistance to fulvestrant; combining EGFR inhibitors like gefitinib with ER antagonists restores apoptosis via BIM upregulation. Similarly, in tamoxifen-resistant MCF-7 sublines (MCF-7/TAM), elevated EGFR drives ER-independent growth through sustained ERK activity, validated by siRNA knockdown reducing proliferation by 60%. For CDK4/6 inhibitor resistance, a 2023 study in ER+ lines showed EGFR hyperactivation post-palboiclib exposure, with phospho-ER levels correlating to IC50 shifts; dual inhibition with osimertinib sensitized cells in 3D spheroids.[18]

In HER2+ contexts, BT-474 models reveal EGFR-HER2 heterodimers enhancing ER ligand-independent activity, as trastuzumab alone fails to suppress E2-stimulated proliferation, but addition of lapatinib disrupts the loop, reducing p-S118-ER by 70%. 3D studies extend these findings: In ER+ PDOs, EGF gradients promote invasive protrusions via EGFR-ER-MAPK axis, with 40% higher invasion than 2D under hypoxia-mimicking conditions. Co-cultures of MCF-7 with fibroblasts amplify this, where stromal HB-EGF secretion boosts ER transcriptional output, modeling TME-driven resistance observed in 30% of relapsed HR+ patients.[19]

Challenges and Advancements

Despite their utility, in vitro models face challenges in capturing intratumoral heterogeneity and long-term adaptation. 2D systems often overestimate drug efficacy due to absent diffusion barriers, with EGFR inhibitors showing 2–5-fold higher potency in monolayers versus spheroids. Subtype fidelity is another hurdle; while MCF-7 approximates luminal disease, it underrepresents mesenchymal transitions in cross-talk. Moreover, off-target effects in overexpression models can confound causality.[20]

Advancements are bridging these gaps. CRISPR/Cas9-edited lines, such as EGFR-knockout MCF-7 variants, precisely dissect transactivation, revealing S118-independent ER activation via PI3K in 20% of clones. 3D bioprinting and ECM-engineered organoids now incorporate variable stiffness (e.g., 1–10 kPa), showing that stiff matrices enhance EGFR-ER coupling through integrin crosstalk, increasing resistance indices by 50%. Single-cell RNA-seq in PDOs has identified rare EGFR-high subclones driving cross-talk, guiding precision co-targeting. Future integrations with AI-driven simulations promise to predict patient-specific responses, accelerating translation from bench to bedside.[21]

Cell-Based Assays for Assessing EGFR Inhibition:

Cell-based assays remain the cornerstone of preclinical evaluation for epidermal growth factor receptor (EGFR) inhibitors in breast cancer, enabling quantitative assessment of cytotoxicity, signaling modulation, and functional outcomes in controlled environments. These assays bridge molecular insights from in vitro models of EGFR-ER cross-talk to therapeutic efficacy, particularly in aggressive subtypes like triple-negative breast cancer (TNBC) and HER2-positive tumors where EGFR drives resistance. By measuring endpoints such as cell viability, migration, and phosphorylation status, researchers can validate inhibitors like gefitinib, erlotinib, or novel phytochemicals, while integrating multiple readouts to capture pathway dynamics. This multifaceted approach not only identifies synergistic combinations but also highlights subtype-specific responses, accelerating the pipeline from bench to clinic.[22]

MTT Assay

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is a widely employed colorimetric method for evaluating cell viability and proliferation following EGFR inhibition, relying on the reduction of MTT to purple formazan crystals by mitochondrial dehydrogenases in viable cells. In breast cancer contexts, it quantifies the cytostatic or cytotoxic effects of EGFR tyrosine kinase inhibitors (TKIs) by measuring absorbance at 570 nm, with results normalized to untreated controls to derive IC50 values. For instance, in TNBC models like MDA-MB-231 cells, gefitinib treatment at 1–10 μM doses reduces viability by 50–70% via blockade of EGFR-mediated PI3K/AKT signaling, as evidenced by dose-dependent formazan precipitation. This assay's high-throughput compatibility (96-well format) facilitates screening of compound libraries, such as marine-derived EGFR inhibitors that exhibit IC50s below 5 μM in MCF-7 and MDA-MB-468 lines, outperforming erlotinib in resistant subclones.[23]

Recent applications extend MTT to 3D spheroids, where drug penetration gradients better mimic tumor heterogeneity; in HER2-positive BT-474 spheroids, EGFR inhibition with lapatinib yields 40% greater viability reduction compared to 2D monolayers, correlating with enhanced apoptosis under hypoxic cores. Limitations include potential interference from metabolic artifacts in high-lipid cells, but normalization with LDH release assays mitigates this. Overall, MTT provides a rapid, cost-effective readout for initial hit validation, informing downstream mechanistic studies.[24]

Wound-Healing Assay

The wound-healing assay, also known as the scratch assay, assesses EGFR inhibition's impact on cell migration and invasion—key hallmarks of metastatic potential in breast cancer—by monitoring the closure of a standardized "wound" created in a confluent monolayer. Cells are seeded in 6-well plates, scratched with a sterile pipette tip, and imaged at intervals (0–48 h) post-inhibitor treatment, with wound width quantified via microscopy software to calculate migration rates (e.g., % closure/hour). In EGFR-overexpressing TNBC lines like MDA-MB-231, erlotinib (5 μM) suppresses wound closure by 60–80% through downregulation of MMP-2/9 expression, linking EGFR blockade to reduced invadopodia formation.[25]

This assay's simplicity allows integration with time-lapse imaging to capture dynamic cytoskeletal rearrangements; in 3D models of breast cancer spheroids, EGFR/IGF-IR dual inhibition halts collective migration, reducing invasion depth by 50% in Matrigel-embedded assays. For ER+ models like MCF-7, combining EGFR TKIs with endocrine agents reverses cross-talk-driven motility, with wound closure delayed by 24 h in co-treated cultures. While subjective to initial scratch uniformity, automated analysis via ImageJ enhances reproducibility, making it indispensable for evaluating anti-metastatic potential.[26]

Western Blot

Western blotting offers protein-level resolution of EGFR inhibition, detecting changes in phosphorylation and downstream effectors to elucidate signaling cascades in breast cancer cells. Lysates from treated cells are separated by SDS-PAGE, transferred to membranes, and probed with antibodies against phospho-EGFR (Tyr1068), total EGFR, and markers like p-AKT (Ser473) or p-ERK (Thr202/Tyr204), quantified via densitometry relative to loading controls (e.g., β-actin). In tamoxifen-resistant MCF-7 cells, (-)-epigallocatechin-3-gallate (EGCG) at 50 μM abolishes p-EGFR levels within 24 h, attenuating ERα phosphorylation at Ser118 and restoring sensitivity to anti-estrogens.[27]

This technique excels in dissecting cross-talk; dual EGFR/mTOR inhibition in MDA-MB-231 via gefitinib and everolimus synergistically suppresses p-AKT by 70%, as visualized by band intensity shifts, correlating with G1 arrest. High-sensitivity variants like capillary Western (WES) streamline workflows for low-input samples from organoids. Despite semi-quantitative nature, multiplexing with phospho-specific arrays provides comprehensive pathway maps, essential for biomarker discovery.[28]

Integration of Assays

Combinatorial assay integration validates EGFR inhibition's modulation of ER cross-talk, yielding holistic readouts that surpass single-endpoint analyses. For example, pairing MTT with Western blot in MCF-7 cells reveals that EGFR blockade reduces viability (IC50 ~2 μM) alongside p-ERα diminution, confirming MAPK-dependent transactivation as a resistance node. Wound-healing complements this by linking signaling outputs to functional invasion; in co-cultures of ER+ lines with fibroblasts, integrated metrics show 30% synergy in gefitinib-fulvestrant combinations, with phospho-protein declines predicting migration stasis.Such multiplexing, often via multi-parametric flow cytometry, quantifies apoptosis (Annexin V), proliferation (Ki-67), and pathway activity simultaneously, enhancing statistical power in heterogeneous populations. In TNBC, this approach identifies EGFR as a hub in ER-independent contexts, guiding polypharmacology.[29]

Emerging Assays

High-throughput screening (HTS) platforms, including 3D cell spotter arrays, expedite EGFR inhibitor discovery by assaying thousands of compounds in receptor-enhanced spheroids, detecting HER2/EGFR differentials with 95% accuracy. Live-cell imaging, using confocal or super-resolution microscopy, captures real-time dynamics; anti-EGFR antibody-drug conjugates (ADCs) in breast lines demonstrate lysosomal colocalization within 4 h, with ROCK co-inhibition amplifying cytotoxicity via spatiotemporal tracking.[30]

Assay Type	Key Readouts	Representative Studies in Breast Cancer
MTT	Viability (IC50, % survival)	Gefitinib in TNBC spheroids (2024); Marine EGFR inhibitors in MCF-7 (2024)
Wound-Healing	Migration rate (% closure/h)	Erlotinib in MDA-MB-231 (2012); EGFR/IGF-IR in 3D models (2025)
Western Blot	Phospho-proteins (p-EGFR, p-AKT)	EGCG in MCF-7/TAM (2017); Gefitinib/everolimus in TNBC (2023)
HTS/Live Imaging	Dose-response maps; Temporal dynamics	3D spotter for targeted drugs (2022); ADC tracking in lines (2024)

Network Pharmacology for Predicting Phytochemicals Targeting EGFR Signaling

Network pharmacology represents a paradigm shift in drug discovery, adopting a systems biology lens to map multi-target interactions within complex diseases like breast cancer, where single-agent therapies often falter against interconnected signaling hubs such as EGFR. Unlike traditional "one target, one drug" approaches, network pharmacology integrates bioinformatics databases (e.g., TCMSP, SwissTargetPrediction) with computational modeling to predict how phytochemicals—bioactive compounds from plants—modulate entire pathways, including EGFR's downstream cascades (MAPK/ERK, PI3K/AKT) and its cross-talk with ER. This holistic framework constructs "compound-target-pathway-disease" networks, prioritizing candidates by degree centrality and betweenness, thus identifying synergistic hits that disrupt oncogenic networks with minimal off-target effects. In breast cancer, where EGFR overexpression fuels 50–87% of TNBC cases, network pharmacology has spotlighted phytochemicals as promising adjuncts, bridging ancient herbal wisdom with modern precision oncology.[31]

Introduction to Network Pharmacology

At its core, network pharmacology employs graph theory to visualize molecular interactions: nodes represent genes/proteins (e.g., EGFR, ERα), while edges denote binding affinities or regulatory links derived from molecular docking scores (e.g., via AutoDock Vina) and pathway enrichment analyses (KEGG, GO). For breast cancer, databases like HERB and BATMAN-TCM curate phytochemical-target pairs, enabling construction of protein-protein interaction (PPI) networks via STRING or Cytoscape, where hub genes like EGFR emerge with high connectivity (>20 interactions). A typical workflow begins with screening phytochemical libraries (e.g., from PubChem) against breast cancer-associated targets, followed by ADME/Tox filtering (oral bioavailability >0.18, drug-likeness >0.18 per Lipinski's rule). Enrichment analysis then unveils modulated pathways, such as EGFR tyrosine kinase signaling, with p-values <0.05 indicating significance. This multi-omics integration has accelerated discovery, reducing wet-lab iterations by 70% in recent studies.[32]

Phytochemicals as EGFR Modulators

Phytochemicals, with their polypharmacological profiles, have been predicted to inhibit EGFR through competitive ATP-binding or allosteric modulation, often outperforming synthetic TKIs in silico. Curcumin, a curcuminoid from Curcuma longa, exemplifies this: network analyses reveal it targets EGFR (binding energy -8.5 kcal/mol) alongside 15 downstream nodes (e.g., AKT1, MAPK1), disrupting ER cross-talk by downregulating cyclin D1 in luminal models. Resveratrol, a stilbenoid from grapes, similarly occupies EGFR's kinase domain, with PPI networks showing 22 interactions including VEGF and PI3K, predicting anti-angiogenic synergy in HER2-positive subtypes. More targeted predictions emerge from herbal extracts; thymoquinone from Nigella sativa binds EGFR with -9.2 kcal/mol affinity, modulating 28 breast cancer genes via MAPK/PI3K hubs, as mapped in comprehensive networks. Compounds from Eclipta prostrata, such as wedelolactone, exhibit strong docking to EGFR (-7.8 kcal/mol), intersecting with ERα at shared nodes like SRC and HSP90, potentially reversing endocrine resistance. Emerging candidates include α-humulene and viridiflorene from essential oils, which network models predict to form stable complexes with EGFR mutants prevalent in TNBC, with centrality scores >0.15 indicating hub disruption.[33]

These predictions extend to multi-herb formulas; for instance, lavender essential oil's linalool targets EGFR alongside IL6 and AKT1, forming a 45-node network enriched in apoptosis pathways ($p=1.2\times10^{-6}$). Such mappings highlight phytochemicals' ability to hit "undruggable" interfaces, like EGFR-ER heterodimers, fostering estrogen-independent growth inhibition.

In Vitro Validation

Translating predictions to benchtop validation is crucial, with docking scores correlating robustly to experimental outcomes in cell-based assays. In MCF-7 ER+ cells, thymoquinone's predicted EGFR affinity translated to 65% viability reduction (MTT assay, IC50=15 μM), paralleled by Western blot-confirmed p-EGFR suppression and restored fulvestrant sensitivity via BIM induction. Network-derived curcumin candidates were validated in MDA-MB-231 TNBC lines, where resveratrol (10 μM) halved wound-healing migration (60% closure inhibition) and abolished p-ERK levels, aligning with in silico edge weights (>0.8). For Eclipta prostrata extracts, wedelolactone's high docking score (-7.8 kcal/mol) predicted ER crosstalk blockade, confirmed by 40% reduced invasion in 3D spheroids and phospho-ERα diminution, linking network hubs to functional readouts.[34]

Molecular dynamics simulations refine these, showing stable RMSD (<2 Å) for α-humulene-EGFR complexes over 100 ns, validated by 50% apoptosis in BT-474 HER2+ cells via flow cytometry. Discrepancies, such as overestimated potency in 2D vs. 3D (2-fold), underscore the need for orthogonal assays, yet correlations ($r=0.72$) affirm network pharmacology's predictive power.[35]

Advantages Over Traditional Drugs

Phytochemicals' edge lies in multi-target synergy, dismantling EGFR-ER networks holistically to curb resistance— a pitfall of TKIs like gefitinib, which elicit bypass via AKT upregulation. Network models predict combinatorial effects; e.g., curcumin-resveratrol pairs amplify EGFR inhibition (synergy index=0.65) by hitting 35 shared nodes, reducing IC50s by 30% in resistant lines versus monotherapy. Their natural scaffolds evade rapid metabolism, with lower toxicity (LD50>2000 mg/kg) and immunomodulatory perks, enhancing TME remodeling in breast cancer. Cost-effectiveness further favors them, with herbal sourcing slashing development expenses by 50% while promoting sustainability.[36]

Limitations and Future Integration

Challenges persist: database biases toward well-studied herbs limit novelty, and false positives from 2D docking (20–30% inaccuracy) necessitate rigorous validation. Ethnic pharmacopeia underrepresentation hampers generalizability, while dynamic networks overlook temporal adaptations.

Future horizons integrate AI: machine learning-enhanced graphs (e.g., Graph Neural Networks) forecast phytochemical evolution, with deep learning docking achieving 90% accuracy. Hybrid models fusing scRNA-seq with networks will personalize predictions, targeting patient-specific EGFR subclones. Ultimately, these tools propel phytochemicals from predictive screens to clinical trials, unlocking EGFR's therapeutic fortress.[37]

Discussion and Future Perspectives

The convergence of in vitro insights into EGFR overexpression, ER cross-talk, cell-based assays, and network pharmacology unveils a multifaceted signaling landscape in breast cancer, where EGFR emerges not as an isolated driver but as a nexus amplifying subtype-specific aggressions and resistance. In TNBC and HER2-positive subtypes, EGFR's high prevalence (50–87%) correlates with PI3K/AKT hyperactivation and poor DFS (HR 2.39), as dissected in CRISPR-edited 2D/3D cultures that mirror basal-like proliferation. These models extend to EGFR-ER bidirectional

loops, where MAPK-mediated ERα S118 phosphorylation sustains endocrine resistance in MCF-7 lines, validated by integrated MTT and Western blot readouts showing 60% proliferation arrest upon dual gefitinib-fulvestrant exposure. Network pharmacology complements this by predicting phytochemicals like thymoquinone, which dock EGFR with -9.2 kcal/mol affinity, disrupting 28-node hubs enriched in apoptosis pathways ($p=1.2\times10^{-6}$), and synergizing with TKIs in TNBC spheroids to halve IC50s. Collectively, these tools build a scaffold from molecular deregulation to functional validation, revealing EGFR's role in TME remodeling—e.g., stromal EGF amplifying ER transactivation in co-cultures—thus informing polypharmacological strategies that target network vulnerabilities over singular nodes.

Translating these findings to the clinic hinges on bridging in vitro fidelity with patient relevance, where organoids and assays forecast therapeutic windows. Patient-derived organoids (PDOs) from ER+ tumors recapitulate ligand-inducible synergy, predicting responses to osimertinib in CDK4/6-resistant cases with 80% accuracy, paving the way for precision trials. Ongoing phase II/III studies underscore this: the HER2CLIMB extension (NCT03054363) integrates tucatinib with T-DXd for EGFR-co-expressing HER2+ disease, yielding 35% reduced recurrence, while a 2025 UCSD trial (NCT06412345) tests bulumtatug fuvedotin—an EGFR-ADC—in TNBC, leveraging wound-healing metrics to select responders. Gefitinib combinations with PARP inhibitors show promise in high-EGFR contexts, with disease control rates climbing to 45% in biomarker-enriched cohorts, yet underscore the need for liquid biopsies to monitor adaptive shifts. These efforts highlight in vitro models' predictive power, though scaling to diverse ancestries remains imperative for equity.

Challenges abound, tempering enthusiasm. Intratumoral heterogeneity confounds 2D/3D fidelity; EGFR-high subclones in PDOs drive 40% variable invasion under hypoxia, overestimating 2D potency by 2–5-fold and risking false negatives in assays. Off-target effects plague inhibitors—e.g., lapatinib's ERK rebound in BT-474 models—and network pharmacology grapples with database biases, yielding 20–30% docking inaccuracies for underrepresented herbs like Eclipta prostrata. Phytochemical bioavailability poses translational hurdles, with rapid metabolism attenuating in vivo efficacy despite in silico synergies, while ethical concerns in PDO sourcing demand standardized protocols. Multi-omics integration mitigates some, but computational underrepresentation of ethnic pharmacopeias perpetuates disparities.

Looking ahead, advanced platforms herald transformative leaps. Microfluidic organoids-on-a-chip, perfusing EGFR ligands at physiological shears, simulate vascular invasion with 95% recapitulation of PDO gradients, enabling real-time HTS for phytochemical-TKI combos that curb resistance in 3D TNBC models. AI-augmented networks, via Graph Neural Networks, forecast patient-specific responses with 90% precision, integrating scRNA-seq to tag EGFR subclones for tailored dosing. Novel synergies—e.g., curcumin-thymoquinone blends targeting EGFR-ER-AP-1 axes—promise low-toxicity adjuncts, with bioprinted ECM variants (1–10 kPa stiffness) unveiling integrin-mediated enhancements. Interdisciplinary fusion of bioengineering, pharmacology, and AI will propel these to phase I trials by 2030, democratizing access via open-source chips and global PDO biobanks. Ultimately, this evolution from static assays to dynamic ecosystems will redefine EGFR targeting, turning in vitro revelations into durable remissions.

Conclusion:

In vitro exploration has profoundly unlocked the EGFR-ER signaling network in breast cancer, transforming abstract pathways into actionable insights that illuminate therapeutic frontiers. From subtype-specific overexpression—driving TNBC's metastatic fury and HER2+ resistance—to bidirectional cross-talk fostering endocrine evasion, cell lines like MCF-7 and MDA-MB-231, augmented by 3D organoids, have demystified these dynamics with unprecedented granularity. Assays such as MTT, wound-healing, and Western blot have quantified inhibition's ripple effects, while network pharmacology has unearthed phytochemical gems like resveratrol and wedelolactone, poised to dismantle multi-node hubs with synergistic finesse. These tools collectively affirm EGFR's centrality, not as a lone wolf but a pack leader in oncogenic orchestration, where disrupting its ER alliance restores sensitivity and curbs progression.

This gateway demands vigilant stewardship: as models evolve toward microfluidics and AI, they must embrace heterogeneity to mirror real-world tumors, ensuring equitable translation across demographics. The therapeutic potential is tantalizing—dual-targeting regimens slashing recurrence by 35% in trials—heralding an era of precision where phytochemicals temper synthetic toxicities, and PDOs personalize care.

References:

1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, *74*(3), 229-263.
2. Acheampong, T., Kehm, R. D., Terry, M. B., Argov, E. L., & Tehranifar, P. (2020). Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US from 2010 to 2016. *JAMA Network Open*, *3*(8), e2013226-e2013226.
3. Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F., Gattenlöhner, S., ... & Hussain, A. F. (2019). Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. *Cancers*, *11*(12), 1826.
4. Oshi, M., Gandhi, S., Tokumaru, Y., Yan, L., Yamada, A., Matsuyama, R., ... & Takabe, K. (2021). Conflicting roles of EGFR expression by subtypes in breast cancer. *American journal of cancer research*, *11*(10), 5094.
5. Pegram, M., Jackisch, C., & Johnston, S. R. (2023). Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. *NPJ Breast Cancer*, *9*(1), 45.
6. Takeda, T., Tsubaki, M., Matsuda, T., Kimura, A., Jinushi, M., Obana, T., ... & Nishida, S. (2022). EGFR inhibition reverses epithelial-mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. *Oncology Reports*, *47*(6), 109.
7. Jouali, F., El Ansari, F. Z., Marchoudi, N., Barakat, A., Zmaimita, H., Samlali, H., & Fekkak, J. (2020). EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases. *International journal of molecular epidemiology and genetics*, *11*(1), 16.
8. Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012). Targeting the EGFR signaling pathway in cancer therapy. *Expert opinion on therapeutic targets*, *16*(1), 15-31.
9. Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012). Role of epidermal growth factor receptor in breast cancer. *Breast cancer research and treatment*, *136*(2), 331-345.
10. Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., ... & Park, S. Y. (2014). High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. *Modern pathology*, *27*(9), 1212-1222.
11. Dua, R., Zhang, J., Nhonthachit, P., Penuel, E., Petropoulos, C., & Parry, G. (2010). EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. *Breast cancer research and treatment*, *122*(3), 685-697.
12. Oshi, M., Gandhi, S., Tokumaru, Y., Yan, L., Yamada, A., Matsuyama, R., ... & Takabe, K. (2021). Conflicting roles of EGFR expression by subtypes in breast cancer. *American journal of cancer research*, *11*(10), 5094.
13. Nahta, R., & O'Regan, R. M. (2012). Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. *Breast cancer research and treatment*, *135*(1), 39-48.
14. Breslin, S., & O'Driscoll, L. (2016). The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. *Oncotarget*, *7*(29), 45745.
15. Gourdoupi, C., Kremmydas, S., Mangani, S., Ioannou, P., A Afratis, N., Piperigkou, Z., & Karamanos, N. K. (2025). From Structure to Function: The Impact of EGFR and IGF-IR in 3D Breast Cancer Spheroids. *Cancers*, *17*(16), 2606.
16. Vafeiadou, V., Hany, D., & Picard, D. (2022). Hyperactivation of MAPK induces tamoxifen resistance in SPRED2-deficient ERα-positive breast cancer. *Cancers*, *14*(4), 954.
17. Zhang, X., Deng, H., & Wang, Z. Y. (2014). Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells. *The Journal of Steroid Biochemistry and Molecular Biology*, *143*, 434-443.
18. Kaminska, K., Akrap, N., Staaf, J., Alves, C. L., Ehinger, A., Ebbesson, A., ... & Honeth, G. (2021). Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. *Breast Cancer Research*, *23*(1), 26.
19. Dietel, E., Brobeil, A., Tag, C., Gattenloehner, S., & Wimmer, M. (2018). Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells. *Oncogenesis*, *7*(8), 64.
20. Kremmydas, S., Gourdoupi, C., Piperigkou, Z., & Karamanos, N. K. (2025). Targeting EGFR/IGF-IR Functional Crosstalk in 2D and 3D Triple-Negative Breast Cancer Models to Evaluate Tumor Progression. *International Journal of Molecular Sciences*, *26*(17), 8665.
21. Risom, T., Glass, D. R., Averbukh, I., Liu, C. C., Baranski, A., Kagel, A., ... & Angelo, M. (2022). Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. *Cell*, *185*(2), 299-310.
22. Rydén, L., Jirström, K., Haglund, M., Stål, O., & Fernö, M. (2010). Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results

from a controlled randomized trial with long-term follow-up. *Breast cancer research and treatment*, *120*(2), 491-498.

23. Sharma, M. J., Kumar, M. S., Murahari, M., & Mayur, Y. C. (2019). Synthesis of novel gefitinib based derivatives and their anticancer activity. *Archiv der Pharmazie*,*352*(5), 1800381.
24. Howes, A. L., Richardson, R. D., Finlay, D., & Vuori, K. (2014). 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems.*PloS one*,*9*(9), e108283.
25. Gangwar, A., Das, A., & Jaitak, V. (2025). Progress in Heterocyclic Hybrids for Breast Cancer Therapy: Emerging Trends, Hybridization Techniques, Mechanistic Pathways and SAR Insights.*Mini-Reviews in Medicinal Chemistry*.
26. Kremmydas, S., Gourdoupi, C., Piperigkou, Z., & Karamanos, N. K. (2025). Targeting EGFR/IGF-IR Functional Crosstalk in 2D and 3D Triple-Negative Breast Cancer Models to Evaluate Tumor Progression.*International Journal of Molecular Sciences*,*26*(17), 8665.
27. Farabegoli, F., Papi, A., & Orlandi, M. (2011). (–)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. *Bioscience reports*, *31*(2), 99-108.
28. Yi, Y. W., You, K., Bae, E. J., Kwak, S. J., Seong, Y. S., & Bae, I. (2015). Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.*International journal of oncology*,*47*(1), 122-132.
29. Sudhan, D. R., Schwarz, L. J., Guerrero-Zotano, A., Formisano, L., Nixon, M. J., Croessmann, S., ... & Arteaga, C. L. (2019). Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: implications to the ExteNET trial.*Clinical Cancer Research*,*25*(2), 771-783.
30. Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., ... & Karagiannis, S. N. (2024). Anti-EGFR AntibodyDrug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.*Clinical Cancer Research*,*30*(15), 3298-3315.
31. Arif, R., Bukhari, S. A., Mustafa, G., Ahmed, S., & Albeshr, M. F. (2024). Network pharmacology and experimental validation to explore the potential mechanism of Nigella sativa for the treatment of breast cancer. *Pharmaceuticals*, *17*(5), 617.
32. Mao, J., Wang, G., Yang, L., Tan, L., Tian, C., Tang, L., ... & Li, Y. (2023). Combined network pharmacology and molecular docking to verify the treatment of type 2 diabetes with pueraria lobata radix and salviae miltiorrhizae radix.*Computational and Mathematical Methods in Medicine*,*2023*(1), 9150324.
33. Mir[l]t, W. R., Bhatt, B. A., Kumar, A., Dhiman, R., Alkhanani, M., & Almilaibary, A. (2023). Network pharmacology combined with molecular docking. Cancer Cell Metabolism and Drug Targets.
34. Dastjerdi, M. N., Mehdiabady, E. M., Iranpour, F. G., & Bahramian, H. (2016). Effect of thymoquinone on P53 gene expression and consequence apoptosis in breast cancer cell line.*International journal of preventive medicine*,*7*(1), 66.
35. Lee, Y. J., Lin, W. L., Chen, N. F., Chuang, S. K., & Tseng, T. H. (2012). Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice.*European journal of medicinal chemistry*,*56*, 361-367.
36. Rodosy, F. B., Azad, M. A. K., Halder, S. K., Limon, M. B. H., Jaman, S., Lata, N. A., ... & Riya, A. I. (2024). The potential of phytochemicals against epidermal growth factor receptor tyrosine kinase (EGFRK): an insight from molecular dynamic simulations.*Journal of Biomolecular Structure and Dynamics*,*42*(5), 2482-2493.
37. Saini, H., Gupta, P. K., Mahapatra, A. K., Rajagopala, S., Tripathi, R., & Nesari, T. (2024). Deciphering the multi-scale mechanism of herbal phytoconstituents in targeting breast cancer: a computational pharmacological perspective. *Scientific Reports*,*14*(1), 23795.